201 related articles for article (PubMed ID: 38420162)
1. Multi-omics analysis of disulfidptosis regulators and therapeutic potential reveals glycogen synthase 1 as a disulfidptosis triggering target for triple-negative breast cancer.
Xie J; Deng X; Xie Y; Zhu H; Liu P; Deng W; Ning L; Tang Y; Sun Y; Tang H; Cai M; Xie X; Zou Y
MedComm (2020); 2024 Mar; 5(3):e502. PubMed ID: 38420162
[TBL] [Abstract][Full Text] [Related]
2. Pan-cancer genetic analysis of disulfidptosis-related gene set.
Liu H; Tang T
Cancer Genet; 2023 Nov; 278-279():91-103. PubMed ID: 37879141
[TBL] [Abstract][Full Text] [Related]
3. Molecular landmarks of tumor disulfidptosis across cancer types to promote disulfidptosis-target therapy.
Zhao D; Meng Y; Dian Y; Zhou Q; Sun Y; Le J; Zeng F; Chen X; He Y; Deng G
Redox Biol; 2023 Dec; 68():102966. PubMed ID: 38035663
[TBL] [Abstract][Full Text] [Related]
4. Construction of a novel disulfidptosis-related signature for improving outcomes in hepatocellular carcinoma: Observational study.
Chen X; Liang Q; Zhou Y
Medicine (Baltimore); 2023 Oct; 102(40):e35423. PubMed ID: 37800779
[TBL] [Abstract][Full Text] [Related]
5. Integrating bulk-seq and single-cell-seq reveals disulfidptosis potential index associating with neuroblastoma prognosis and immune infiltration.
Zhu A; Li X; Wang J
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16647-16658. PubMed ID: 37721569
[TBL] [Abstract][Full Text] [Related]
6. Single-cell disulfidptosis regulator patterns guide intercellular communication of tumor microenvironment that contribute to kidney renal clear cell carcinoma progression and immunotherapy.
Xu K; Li D; Qian J; Zhang Y; Zhang M; Zhou H; Hou X; Jiang J; Zhang Z; Sun H; Shi G; Dai H; Liu H
Front Immunol; 2024; 15():1288240. PubMed ID: 38292868
[TBL] [Abstract][Full Text] [Related]
7. Single-cell sequencing and bulk RNA data reveal the tumor microenvironment infiltration characteristics of disulfidptosis related genes in breast cancer.
Chen Y; Jin C; Cui J; Diao Y; Wang R; Xu R; Yao Z; Wu W; Li X
J Cancer Res Clin Oncol; 2023 Oct; 149(13):12145-12164. PubMed ID: 37428249
[TBL] [Abstract][Full Text] [Related]
8. Disulfidptosis characterizes the tumor microenvironment and predicts immunotherapy sensitivity and prognosis in bladder cancer.
Pan G; Xie H; Xia Y
Heliyon; 2024 Feb; 10(3):e25573. PubMed ID: 38356551
[TBL] [Abstract][Full Text] [Related]
9. Bioinformatics-based analysis of the relationship between disulfidptosis and prognosis and treatment response in pancreatic cancer.
Xiong Y; Kong X; Mei H; Wang J; Zhou S
Sci Rep; 2023 Dec; 13(1):22218. PubMed ID: 38097783
[TBL] [Abstract][Full Text] [Related]
10. Exploring the role of disulfidptosis-related signatures in immune microenvironment, prognosis and therapeutic strategies of cervical cancer.
Jin T; Yin T; Xu R; Liu H; Yuan S; Xue Y; Zhang J; Wang H
Transl Oncol; 2024 Jun; 44():101938. PubMed ID: 38492499
[TBL] [Abstract][Full Text] [Related]
11. Identification a unique disulfidptosis classification regarding prognosis and immune landscapes in thyroid carcinoma and providing therapeutic strategies.
Feng Z; Zhao Q; Ding Y; Xu Y; Sun X; Chen Q; Zhang Y; Miao J; Zhu J
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11157-11170. PubMed ID: 37347261
[TBL] [Abstract][Full Text] [Related]
12. Development of a novel disulfidptosis-related lncRNA signature for prognostic and immune response prediction in clear cell renal cell carcinoma.
Wang N; Hu Y; Wang S; Xu Q; Jiao X; Wang Y; Yan L; Cao H; Shao F
Sci Rep; 2024 Jan; 14(1):624. PubMed ID: 38182642
[TBL] [Abstract][Full Text] [Related]
13. Pancancer analysis reveals the role of disulfidptosis in predicting prognosis, immune infiltration and immunotherapy response in tumors.
Huang J; Xu Z; Chen D; Zhou C; Shen Y
Medicine (Baltimore); 2023 Dec; 102(52):e36830. PubMed ID: 38206694
[TBL] [Abstract][Full Text] [Related]
14. Crosstalk of disulfidptosis-related subtypes, establishment of a prognostic signature and immune infiltration characteristics in bladder cancer based on a machine learning survival framework.
Zhao S; Wang L; Ding W; Ye B; Cheng C; Shao J; Liu J; Zhou H
Front Endocrinol (Lausanne); 2023; 14():1180404. PubMed ID: 37152941
[TBL] [Abstract][Full Text] [Related]
15. Integrative analysis of disulfidptosis and immune microenvironment in hepatocellular carcinoma: a putative model and immunotherapeutic strategies.
Yang T; Liu J; Liu F; Lei J; Chen S; Ma Z; Ke P; Yang Q; Wen J; He Y; Duan J; Zeng X
Front Immunol; 2023; 14():1294677. PubMed ID: 38235128
[TBL] [Abstract][Full Text] [Related]
16. Identification of disulfidptosis related subtypes, characterization of tumor microenvironment infiltration, and development of DRG prognostic prediction model in RCC, in which
Xu K; Zhang Y; Yan Z; Wang Y; Li Y; Qiu Q; Du Y; Chen Z; Liu X
Front Immunol; 2023; 14():1205250. PubMed ID: 37426643
[TBL] [Abstract][Full Text] [Related]
17. Construction of disulfidptosis-based immune response prediction model with artificial intelligence and validation of the pivotal grouping oncogene c-MET in regulating T cell exhaustion.
Li P; Wang S; Wan H; Huang Y; Yin K; Sun K; Jin H; Wang Z
Front Immunol; 2024; 15():1258475. PubMed ID: 38352883
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of a disulfidptosis-related scoring system to predict clinical outcome and immunotherapy response in acute myeloid leukemia by integrated analysis of single-cell and bulk RNA-sequencing.
Zhong F; Jiang J; Yao FY; Liu J; Shuai X; Wang XL; Huang B; Wang X
Front Pharmacol; 2023; 14():1272701. PubMed ID: 38053840
[No Abstract] [Full Text] [Related]
19. Leveraging a gene signature associated with disulfidptosis identified by machine learning to forecast clinical outcomes, immunological heterogeneities, and potential therapeutic targets within lower-grade glioma.
Zhou Y; Cao Y; Liu W; Wang L; Kuang Y; Zhou Y; Chen Q; Cheng Z; Huang H; Zhang W; Jiang X; Wang B; Ren C
Front Immunol; 2023; 14():1294459. PubMed ID: 38162649
[TBL] [Abstract][Full Text] [Related]
20. Disulfidptosis classification of hepatocellular carcinoma reveals correlation with clinical prognosis and immune profile.
Wang T; Guo K; Zhang D; Wang H; Yin J; Cui H; Wu W
Int Immunopharmacol; 2023 Jul; 120():110368. PubMed ID: 37247499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
